Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tibur Schmidlin is active.

Publication


Featured researches published by Tibur Schmidlin.


Bioorganic & Medicinal Chemistry Letters | 1994

Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series

Peter Dr. Bühlmayer; Pascual Furet; Leoluca Criscione; Marc de Gasparo; Steven Whitebread; Tibur Schmidlin; Rene Lattmann; Jeanette Marjorie Wood

Abstract Starting from the structure of DuP-753 and a 3-dimensional model of the pentapeptide Tyr-Ile-His-Pro-Ile, a series of new and highly potent antagonists has been designed where the imidazole moiety of the Du Pont compound has been replaced by an N-acylated aminoacid residue. VALSARTAN (Ex. 4e CGP48933, (S)-N-Valeryl-N-[2′-(1H-tetrazol-5-yl-)biphenyl-4-yl]methyl-valine), has been selected for clinical investigation.


Bioorganic & Medicinal Chemistry Letters | 2000

Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.

Heinrich Rueeger; Pascal Rigollier; Yasuchika Yamaguchi; Tibur Schmidlin; Walter Schilling; Leoluca Criscione; Steven Whitebread; Michele Chiesi; Mary W. Walker; Dale Dhanoa; Imadul Islam; Jack Zhang; Charles Gluchowski

The design of a novel series of NPY-Y5 receptor antagonists is described. Key elements for the design were the identification of weak Y5 hits from a Y1 program, results from a combinatorial approach and database mining. This led to the discovery of the quinazoline 4 and the aryl-sulphonamide moiety as major components of the pharmacophore for Y5 affinity. The synthesis and SAR towards CGP71683A is described.


Archive | 1996

Quinazolin-2,4-diazirines as npy receptor antagonist

Heinrich Rüeger; Tibur Schmidlin; Pascal Rigollier; Yasuchika Yamaguchi; Marina Tintelnot-Blomley; Walter Schilling; Leoluca Criscione


Bioorganic & Medicinal Chemistry Letters | 2004

Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists

Heinrich Rueeger; Marc Gerspacher; Peter Buehlmayer; Pascal Rigollier; Yasuchika Yamaguchi; Tibur Schmidlin; Steven Whitebread; Barbara Nuesslein-Hildesheim; Hanspeter Nick; Leoluca Cricione


Archive | 1992

N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists

Tibur Schmidlin; Paul Zbinden; Peter Dr. Bühlmayer


Archive | 2001

Condensed thiazolamines and their use as neuropeptide y5 antagonists

Tibur Schmidlin; Heinrich Rüeger; Marc Gerspacher


Archive | 1988

Histidinylamino compounds substituted by sulphur-containing groups

Leslie J. Browne; Richard Dr Goeschke; Vittorio Rasetti; Heinrich Rueeger; Tibur Schmidlin


Archive | 1995

N-acyl-N-heterocyclylalkylamino acid compounds and method of use thereof

Tibur Schmidlin; Paul Zbinden; Peter B uhlmayer


Archive | 1993

N-acyl-n-quinolinyl or isoquinounyl alkylamino acids compositions and method of use

Tibur Schmidlin; Paul Zbinden; Peter Dr. Bühlmayer


Archive | 1992

N-acyl-N-heterocyclylalkyamino acids compositions and method of use

Tibur Schmidlin; Paul Zbinden; Peter Dr. Bühlmayer

Collaboration


Dive into the Tibur Schmidlin's collaboration.

Researchain Logo
Decentralizing Knowledge